# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Tycho Peterson maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target fro...
UBS analyst John Sourbeer maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and raises the price target from $7 to $7.5.
Canaccord Genuity analyst Kyle Mikson reiterates Akoya Biosciences (NASDAQ:AKYA) with a Buy and maintains $10 price target.
2024 Financial OutlookThe Company, based on its current plans and initiatives, expects full year 2024 revenue guidance range of...
Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0...
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter.
Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced preliminary unaudited re...